Skip to main content

Table 4 Multivariable analysis of factors affecting antibody titers in HD patients

From: Investigation for the efficacy of COVID-19 vaccine in Japanese CKD patients treated with hemodialysis

Variable

Estimate

Standard variation

p value

VIF

Antibody titer at 2 weeks (multivariable regression analysis)

Dialysis time

0.41

0.20

0.04

1.09

Age

− 0.01

0.01

0.26

1.10

BMI

0.02

0.02

0.22

1.08

Hypertension

0.10

0.07

0.14

1.05

Cardiovascular disease

− 0.09

0.09

0.29

1.11

COPD

0.21

0.14

0.14

1.06

BUN

− 0.004

0.004

0.41

1.08

IgG

0.0002

0.0002

0.31

1.12

Antibody titer at 2 weeks (stepwise regression analysis)

Dialysis time

0.57

0.18

0.002

1.00

Hypertension

0.11

0.07

0.11

1.03

COPD

0.21

0.14

0.14

1.04

Reduction rate of antibody titer (multivariable regression analysis)

COPD

0.24

0.13

0.06

1.03

Hypertension

0.12

0.06

0.05

1.05

Malignant tumor

0.12

0.09

0.18

1.02

BUN

− 0.01

0.004

0.06

1.03

CRP

− 0.12

0.10

0.22

1.01

Reduction rate of antibody titer (stepwise regression analysis)

COPD

0.24

0.13

0.06

1.03

Hypertension

0.13

0.06

0.04

1.04

BUN

− 0.008

0.01

0.05

1.02

  1. VIF, variance inflation factor; IgG, immunoglobulin G; COPD, chronic obstructive pulmonary disease; BUN, blood urea nitrogen; Alb, albumin; UA, uric acid
  2. Statistically significant parts with p < 0.05 were shown in bold